Observational suspected adverse drug reaction profiles of fluoro-pharmaceuticals and potential mimicry of per- and polyfluoroalkyl substances (PFAS) in the United Kingdom
PLOS One · 2025
DOI: 10.1371/journal.pone.0331286 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Banurja Balasubramaniam und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Fluorocarbons. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
The aim of this research is to explore the suspected adverse drug reactions (ADRs) of perfluorinated medicines to determine whether side effects commonly associated with per- and poly-fluoroalkyl substances (PFAS) exposure were correlated to the type or number of fluorine atoms in these medications.
Methods
Thirteen fluorinated drugs and six non-fluorinated (or low fluorinated) comparators were selected after systematic triage. The reported ADR data from the Medicines and Healthcare Products Regulatory Agency’s (MHRA) Yellow Card, and prescribing data from the OpenPrescribing database and the National Health Service Business Service Authority (NHSBSA) over a 5-year period were curated. Prescribing data was used to standardise the ADRs by calculating ADRs/1,000,000 items dispensed for selected system organ classes (SOCs), associated with PFAS exposure, for all 19 drugs. The physiochemical and pharmacological properties of the selected drugs were determined from ChemDraw version 23.1.1, Drug Bank, electronic medicines compendium (EMC) and the chemical database of bioactive molecules with drug-like properties, European Molecular Biology Laboratory (ChEMBL).
Results
Excluding congenital, familial, and genetic disorders, and endocrine disorders, all other SOCs ( n = 5) showed statistical significance ( P < .05) for ADRs/1,000,000 items identified across the 13 fluorinated drugs. It was identified that leflunomide was suspected of more ADRs than other comparator medications, which had the highest suspected ADRs/1,000,000 items dispensed ( n = 343) and lansoprazole had the lowest ( n = 14). Both drugs contain same number of fluorine atoms ( n = 3) and similar type of fluorine moiety (trifluoromethyl, -CF 3 ).
Conclusion
No correlation between the fluorination status of the drugs and the ADRs were found.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
ORCID-Profile: Alan M Jones
Zitieren
APA
Balasubramaniam, B., & Jones, A. M. (2025). Observational suspected adverse drug reaction profiles of fluoro-pharmaceuticals and potential mimicry of per- and polyfluoroalkyl substances (PFAS) in the United Kingdom. PLOS One. https://doi.org/10.1371/journal.pone.0331286
Vancouver
Balasubramaniam B, Jones AM. Observational suspected adverse drug reaction profiles of fluoro-pharmaceuticals and potential mimicry of per- and polyfluoroalkyl substances (PFAS) in the United Kingdom. PLOS One. 2025. doi:10.1371/journal.pone.0331286
BibTeX
@article{Balasubramaniam2025,
author = {Balasubramaniam, Banurja and Jones, Alan M},
title = {Observational suspected adverse drug reaction profiles of fluoro-pharmaceuticals and potential mimicry of per- and polyfluoroalkyl substances (PFAS) in the United Kingdom},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0331286}
}
EUVIMED